56 related articles for article (PubMed ID: 29272054)
1. Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach.
Schiegnitz E; Kämmerer PW; Schön H; Blatt S; Berres M; Sagheb K; Al-Nawas B
J Oral Pathol Med; 2018 Mar; 47(3):268-274. PubMed ID: 29272054
[TBL] [Abstract][Full Text] [Related]
2. Chemerin promotes invasion of oral squamous cell carcinoma by stimulating IL-6 and TNF-α production via STAT3 activation.
Lu Z; Liu J; Wan Q; Wu Y; Wu W; Chen Y
Mol Biol Rep; 2024 Mar; 51(1):436. PubMed ID: 38520551
[TBL] [Abstract][Full Text] [Related]
3. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma.
Bau DT; Lippman SM; Xu E; Gong Y; Lee JJ; Wu X; Gu J
Cancer; 2013 Dec; 119(24):4277-83. PubMed ID: 24105340
[TBL] [Abstract][Full Text] [Related]
4. Role of selected salivary inflammatory cytokines in the diagnosis and prognosis of oral squamous cell carcinoma. A Systematic Review and Meta-analysis.
Benito-Ramal E; Egido-Moreno S; González-Navarro B; Jané-Salas E; Roselló-Llabrés X; López-López J
Med Oral Patol Oral Cir Bucal; 2023 Sep; 28(5):e474-e486. PubMed ID: 37099710
[TBL] [Abstract][Full Text] [Related]
5. Role of Inflammatory Markers in Prognosis of Oral Squamous Cell Carcinoma.
Dantas TS; Barros Silva PG; Lima Verde MEQ; Ribeiro Junior AL; Cunha MDPSS; Mota MRL; Alves APNN; Leitão RFC; Sousa FB
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3635-3642. PubMed ID: 31870104
[TBL] [Abstract][Full Text] [Related]
6. Salivary Interleukin-1 Levels in Oral Squamous Cell Carcinoma: A Case-Control Study.
Vala D; Shah J; Purba AK; Mehta T; Mansata AV; Almalki SA; Makkad RS
J Pharm Bioallied Sci; 2024 Feb; 16(Suppl 1):S346-S348. PubMed ID: 38595589
[TBL] [Abstract][Full Text] [Related]
7. A Case of Esophageal Cancer With Markedly Elevated Soluble Interleukin-2 Receptor: A Potential of Soluble Interleukin-2 Receptor as a Biomarker.
Seto N; Miura K; Jin L; Nakahara M
Cureus; 2024 Apr; 16(4):e57477. PubMed ID: 38699096
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Tumor Necrosis Factor (TNF)-Alpha Pro-inflammatory Cytokines in Healthy and Oral Squamous Cell Carcinoma Patients With and Without Diabetes.
Azimudin R; Palati S; R P
Cureus; 2024 Jan; 16(1):e52890. PubMed ID: 38406163
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of soluble TIM-3 in oral squamous cell carcinoma.
Lu K; Ma H; Wang T; Huang Y; Ru M
Future Oncol; 2022 Jan; ():. PubMed ID: 35051343
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Serum Interleukin-6 Levels in Oral Squamous Cell Carcinoma.
Adachi T; Goda H; Shinriki S; Tokuzen N; Kuribayashi N; Hino S; Nakashiro KI; Uchida D
Cureus; 2024 Feb; 16(2):e54439. PubMed ID: 38510850
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal study on salivary IL-6 trajectories in postoperative OSCC patients after chemotherapy and radiotherapy.
K HS; R G; Ramani P; Veeraraghavan VP
J Stomatol Oral Maxillofac Surg; 2024 May; ():101909. PubMed ID: 38729427
[TBL] [Abstract][Full Text] [Related]
12. Utility of serum homocysteine in oral squamous cell carcinoma patients as a potential biomarker.
Palaskar S; Joshi K; Mukkanwar R; Pawar R; Kulkarni G; Pawar S
J Oral Maxillofac Pathol; 2022; 26(3):335-339. PubMed ID: 36588856
[TBL] [Abstract][Full Text] [Related]
13. Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array.
Malhotra R; Patel V; Chikkaveeraiah BV; Munge BS; Cheong SC; Zain RB; Abraham MT; Dey DK; Gutkind JS; Rusling JF
Anal Chem; 2012 Jul; 84(14):6249-55. PubMed ID: 22697359
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Serum Fucose Level among Oral Squamous Cell Carcinoma Patients: A Case-Control Study.
Ashem A; Mehta DN; Singh DN; Singh KC; Anupriya C; Devi AN
J Pharm Bioallied Sci; 2023 Jul; 15(Suppl 2):S878-S880. PubMed ID: 37694091
[TBL] [Abstract][Full Text] [Related]
15. Screening of plasma IL-6 and IL-17 in Bangladeshi lung cancer patients.
Shill MC; Biswas B; Kamal S; Islam M; Rima SS; Ferdausi FA; Chowdhury Q; Reza HM; Bepari AK
Heliyon; 2023 Oct; 9(10):e20471. PubMed ID: 37810816
[TBL] [Abstract][Full Text] [Related]
16. Salivary IL-6 mRNA is a Robust Biomarker in Oral Squamous Cell Carcinoma.
Márton IJ; Horváth J; Lábiscsák P; Márkus B; Dezső B; Szabó A; Tar I; Piffkó J; Jakus P; Barabás J; Barabás P; Olasz L; Kövér Z; Tőzsér J; Sándor J; Csősz É; Scholtz B; Kiss C
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31766212
[TBL] [Abstract][Full Text] [Related]
17. Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival.
Aarstad HH; Moe SEE; Lybak S; Bruserud Ø; Tvedt THA; Aarstad HJ
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672565
[TBL] [Abstract][Full Text] [Related]
18. Tumour Necrosis Factor Alpha (TNF-α) and Oral Squamous Cell Carcinoma.
Brierly G; Celentano A; Breik O; Moslemivayeghan E; Patini R; McCullough M; Yap T
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980727
[TBL] [Abstract][Full Text] [Related]
19. The Assessment of Serum Cytokines in Oral Squamous Cell Carcinoma Patients: An Observational Prospective Controlled Study.
Caruntu A; Scheau C; Codrici E; Popescu ID; Calenic B; Caruntu C; Tanase C
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143043
[TBL] [Abstract][Full Text] [Related]
20. IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.
Sieviläinen M; Saavalainen J; Adnan-Awad S; Salo T; Al-Samadi A
Front Immunol; 2022; 13():812822. PubMed ID: 35359980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
